{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T11:48:16Z","timestamp":1782820096526,"version":"3.54.5"},"reference-count":55,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Bladder preservation has emerged as an established treatment option for selected patients with muscle-invasive bladder cancer (MIBC), offering durable oncologic control with the potential to maintain native bladder function and quality of life. Over the past several decades, prospective trials and large institutional experiences have refined trimodality therapy (TMT)\u2014maximal transurethral resection followed by definitive radiation therapy with concurrent radiosensitizing systemic therapy\u2014and clarified principles of patient selection, treatment delivery, surveillance, and salvage. Randomized evidence supports combined-modality therapy as the backbone of bladder preservation, and contemporary comparative analyses suggest outcomes comparable to radical cystectomy in appropriately selected populations. This review synthesizes the clinical foundations of bladder preservation, including radiobiologic considerations, advances in radiation technique, and patterns of recurrence following TMT. We discuss outcomes in higher-risk populations, including locally advanced and node-positive disease, and examine the evolving integration of systemic therapies. The emergence of immune checkpoint inhibitors and antibody\u2013drug conjugates in urothelial carcinoma has reshaped the systemic treatment landscape and raises important questions regarding patient selection, sequencing, and the potential expansion of organ-preserving strategies. Finally, we outline future directions\u2014including response-adaptive approaches, advances in image-guided and adaptive radiotherapy, and ctDNA-enabled risk stratification\u2014while emphasizing the need for prospective validation and multidisciplinary collaboration to refine and optimize bladder-preserving care.<\/jats:p>","DOI":"10.3390\/jcm15135101","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T10:01:17Z","timestamp":1782813677000},"page":"5101","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bladder Preservation Therapy in Muscle-Invasive Bladder Cancer: Current Evidence and Future Directions"],"prefix":"10.3390","volume":"15","author":[{"given":"Patrick P.","family":"Carriere","sequence":"first","affiliation":[{"name":"Division of Radiation Oncology, Department of Genitourinary Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Comron J.","family":"Hassanzadeh","sequence":"additional","affiliation":[{"name":"Division of Radiation Oncology, Department of Genitourinary Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1200\/JCO.1998.16.11.3576","article-title":"Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: Initial results of Radiation Therapy Oncology Group 89-03","volume":"16","author":"Shipley","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.eururo.2016.12.020","article-title":"Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience","volume":"71","author":"Giacalone","year":"2017","journal-title":"Eur. Urol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMoa1106106","article-title":"Radiotherapy with or without Chemotherapy in Muscle-Invasive Bladder Cancer","volume":"366","author":"James","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ijrobp.2013.06.2044","article-title":"Randomized Noninferiority Trial of Reduced High-Dose Volume Versus Standard Volume Radiation Therapy for Muscle-Invasive Bladder Cancer: Results of the BC2001 Trial (CRUK\/01\/004)","volume":"87","author":"Huddart","year":"2013","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_5","unstructured":"National Comprehensive Cancer Network (2026, March 01). NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer. Version 2024. Available online: https:\/\/www.nccn.org."},{"key":"ref_6","unstructured":"European Association of Urology (2026, March 01). EAU Guidelines on Muscle-Invasive and Metastatic Bladder Cancer. 2024 Edition. Available online: https:\/\/uroweb.org."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1200\/JCO.2014.57.5548","article-title":"Long-Term Outcomes in Patients with Muscle-Invasive Bladder Cancer After Selective Bladder-Preserving Combined-Modality Therapy: A Pooled Analysis of Radiation Therapy Oncology Group Protocols 8802, 8903, 9506, 9706, 9906, and 0233","volume":"32","author":"Mak","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","article-title":"Oligometastases","volume":"13","author":"Hellman","year":"1995","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"4912","DOI":"10.1200\/JCO.2010.28.4950","article-title":"Radiotherapy with Concurrent Carbogen and Nicotinamide in Bladder Carcinoma","volume":"28","author":"Hoskin","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/j.ijrobp.2021.03.001","article-title":"Long-Term Outcomes of Radical Radiation Therapy with Hypoxia Modification with Biomarker Discovery for Stratification: 10-Year Update of the BCON (Bladder Carbogen Nicotinamide) Phase 3 Randomized Trial (ISRCTN45938399)","volume":"110","author":"Song","year":"2021","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S1470-2045(23)00170-5","article-title":"Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: A multi-institutional propensity score matched and weighted analysis","volume":"24","author":"Zlotta","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.eururo.2011.11.010","article-title":"Long-Term Outcomes of Selective Bladder Preservation by Combined-Modality Therapy for Invasive Bladder Cancer: The MGH Experience","volume":"61","author":"Efstathiou","year":"2012","journal-title":"Eur. Urol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S1470-2045(20)30607-0","article-title":"Hypofractionated radiotherapy in locally advanced bladder cancer: An individual patient data meta-analysis of the BC2001 and BCON trials","volume":"22","author":"Choudhury","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13014-016-0618-6","article-title":"Clinical results of conformal versus intensity-modulated radiotherapy using a focal simultaneous boost for muscle-invasive bladder cancer in elderly or medically unfit patients","volume":"11","author":"Lutkenhaus","year":"2016","journal-title":"Radiat. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.3109\/0284186X.2014.928418","article-title":"A comparison of morbidity following conformal versus intensity-modulated radiotherapy for urinary bladder cancer","volume":"53","author":"Holmberg","year":"2014","journal-title":"Acta Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1200\/JCO.2002.11.027","article-title":"Combined-Modality Treatment and Selective Organ Preservation in Invasive Bladder Cancer: Long-Term Results","volume":"20","author":"Grabenbauer","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1200\/JCO.2010.31.5721","article-title":"Phase II Study of Conformal Hypofractionated Radiotherapy with Concurrent Gemcitabine in Muscle-Invasive Bladder Cancer","volume":"29","author":"Choudhury","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1200\/JCO.18.00537","article-title":"Bladder Preservation with Twice-a-Day Radiation Plus Fluorouracil\/Cisplatin or Once Daily Radiation Plus Gemcitabine for Muscle-Invasive Bladder Cancer: NRG\/RTOG 0712\u2014A Randomized Phase II Trial","volume":"37","author":"Coen","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.eururo.2024.09.006","article-title":"Dose-escalated Adaptive Radiotherapy for Bladder Cancer: Results of the Phase 2 RAIDER Randomised Controlled Trial","volume":"87","author":"Huddart","year":"2024","journal-title":"Eur. Urol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Patel, S.A., Liu, Y., Solanki, A.A., Baumann, B.C., Efstathiou, J.A., Jani, A.B., Chang, A.J., Fischer-Valuck, B., and Royce, T.J. (2023). Bladder only versus bladder plus pelvic lymph node chemoradiation for muscle-invasive bladder cancer. Urol. Oncol. Semin. Orig. Investig., 41.","DOI":"10.1016\/j.urolonc.2022.12.011"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.semradonc.2022.10.005","article-title":"Multidisciplinary Management and Radiotherapy Recommendations for Clinically and Pathologically Node-positive Bladder Cancer","volume":"33","author":"Venkatesulu","year":"2022","journal-title":"Semin. Radiat. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"46","DOI":"10.5489\/cuaj.3583","article-title":"Recommendations for the improvement of bladder cancer quality of care in Canada: A consensus document reviewed and endorsed by Bladder Cancer Canada (BCC), Canadian Urologic Oncology Group (CUOG), and Canadian Urological Association (CUA), December 2015","volume":"10","author":"Kassouf","year":"2016","journal-title":"Can. Urol. Assoc. J."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.eururo.2022.04.017","article-title":"Chemoradiotherapy in Muscle-invasive Bladder Cancer: 10-yr Follow-up of the Phase 3 Randomised Controlled BC2001 Trial","volume":"82","author":"Hall","year":"2022","journal-title":"Eur. Urol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1097\/01.ju.0000093721.23249.c3","article-title":"Organ Conservation in Invasive Bladder Cancer by Transurethral Resection, Chemotherapy and Radiation: Results of a Urodynamic and Quality of Life Study on Long-term Survivors","volume":"170","author":"Zietman","year":"2003","journal-title":"J. Urol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.eururo.2019.11.001","article-title":"Patient-reported Quality of Life Outcomes in Patients Treated for Muscle-invasive Bladder Cancer with Radiotherapy \u00b1 Chemotherapy in the BC2001 Phase III Randomised Controlled Trial","volume":"77","author":"Huddart","year":"2020","journal-title":"Eur. Urol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.ijrobp.2016.08.023","article-title":"Quality of Life in Long-term Survivors of Muscle-Invasive Bladder Cancer","volume":"96","author":"Mak","year":"2016","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.semradonc.2004.07.010","article-title":"Organ preservation by combined modality treatment in bladder cancer: The European perspective","volume":"15","author":"Weiss","year":"2005","journal-title":"Semin. Radiat. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ijrobp.2017.01.239","article-title":"Clinical Outcomes of Image Guided Adaptive Hypofractionated Weekly Radiation Therapy for Bladder Cancer in Patients Unsuitable for Radical Treatment","volume":"98","author":"Hafeez","year":"2017","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"4406","DOI":"10.1200\/JCO.23.00725","article-title":"Bladder-Sparing Treatment with Radical Dose Radiotherapy Is an Effective Alternative to Radical Cystectomy in Patients with Clinically Node-Positive Nonmetastatic Bladder Cancer","volume":"41","author":"Swinton","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3233\/BLC-170137","article-title":"Chemotherapy Versus Chemoradiation for Node-Positive Bladder Cancer: Practice Patterns and Outcomes from the National Cancer Data Base","volume":"3","author":"Haque","year":"2017","journal-title":"Bladder Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1093\/jnci\/djs629","article-title":"Combining Radiotherapy and Cancer Immunotherapy: A Paradigm Shift","volume":"105","author":"Formenti","year":"2013","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e006551","DOI":"10.1136\/jitc-2022-006551","article-title":"Concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder: Results from phase II study, BTCRC-GU15-023","volume":"11","author":"Joshi","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"TPS586","DOI":"10.1200\/JCO.2020.38.6_suppl.TPS586","article-title":"INTACT: Phase III randomized trial of concurrent chemoradiotherapy with or without atezolizumab in localized muscle invasive bladder cancer\u2014SWOG\/NRG1806","volume":"38","author":"Singh","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1200\/JCO.20.03489","article-title":"TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients with Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors","volume":"39","author":"Tagawa","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1056\/NEJMoa2511674","article-title":"Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer","volume":"394","author":"Vulsteke","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"104270","DOI":"10.1016\/j.critrevonc.2024.104270","article-title":"Radiation therapy, tissue radiosensitization, and potential synergism in the era of novel antibody-drug conjugates","volume":"195","author":"Natangelo","year":"2024","journal-title":"Crit. Rev. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Carriere, P.P.J., Alhalabi, O., Kamat, A.M., Gao, J., Goswami, S., Campbell, M.T., Shah, A.Y., Jiang, C.Y., Glover, M., and Bree, K. (2026). CONSOLIDATE: A phase I\/II study of radiotherapy combined with enfortumab vedotin (EV) for locally advanced bladder cancer with paired translational ctDNA and utDNA. J. Clin. Oncol., 44.","DOI":"10.1200\/JCO.2026.44.7_suppl.TPS912"},{"key":"ref_40","first-page":"TPS4623","article-title":"Neoadjuvant stereotactic radiotherapy and enfortumab vedotin: A phase I\/II study for localized, cisplatin ineligible, muscle invasive bladder cancer (STAR-EV)","volume":"43","author":"Zhang","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"TPS885","DOI":"10.1200\/JCO.2026.44.7_suppl.TPS885","article-title":"EV-PRIME: Phase Ib\/II study of enfortumab vedotin and pembrolizumab combined with radiotherapy as a bladder-sparing trimodality therapy in muscle invasive bladder cancer","volume":"44","author":"Koshkin","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/JU.0000000000001696","article-title":"Complications and Outcomes of Salvage Cystectomy after Trimodality Therapy","volume":"206","author":"Pieretti","year":"2021","journal-title":"J. Urol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa2511885","article-title":"ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer","volume":"393","author":"Powles","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nrclinonc.2011.44","article-title":"Oligometastases revisited","volume":"8","author":"Weichselbaum","year":"2011","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.clon.2020.07.008","article-title":"Stereotactic Body Radiation Therapy in the Management of Oligometastatic and Oligoprogressive Bladder Cancer and Other Urothelial Malignancies","volume":"33","author":"Franzese","year":"2021","journal-title":"Clin. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Angrisani, A., Bosetti, D.G., Vogl, U.M., Castronovo, F.M., and Zilli, T. (2024). Oligometastatic Urothelial Cancer and Stereotactic Body Radiotherapy: A Systematic Review and an Updated Insight of Current Evidence and Future Directions. Cancers, 16.","DOI":"10.3390\/cancers16183201"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","article-title":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): A randomised, phase 2, open-label trial","volume":"393","author":"Palma","year":"2019","journal-title":"Lancet"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1200\/JCO.18.02052","article-title":"Early Detection of Metastatic Relapse and Monitoring of Therapeutic Efficacy by Ultra-Deep Sequencing of Plasma Cell-Free DNA in Patients with Urothelial Bladder Carcinoma","volume":"37","author":"Christensen","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.radonc.2013.08.045","article-title":"Adaptive plan selection vs. re-optimisation in radiotherapy for bladder cancer: A dose accumulation comparison","volume":"109","author":"Vestergaard","year":"2013","journal-title":"Radiother. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.clon.2021.03.023","article-title":"Image-guided Adaptive Radiotherapy for Bladder Cancer","volume":"33","author":"Kong","year":"2021","journal-title":"Clin. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.21873\/invivo.13615","article-title":"Transcriptome Analysis in Patients with Muscle-invasive Bladder Cancer","volume":"38","author":"Pepe","year":"2024","journal-title":"In Vivo"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Pepe, L., Fiorentino, V., Pizzimenti, C., Riganati, G., Franchina, M., Micali, M., Russotto, F., Ieni, A., Tuccari, G., and Fadda, G. (2024). The Simultaneous Use of Bladder Epicheck\u00ae and Urinary Cytology Can Improve the Sensitivity and Specificity of Diagnostic Follow-Up of Urothelial Lesions: Up-to-Date Data from a Multi-Institutional Cohort. Diseases, 12.","DOI":"10.3390\/diseases12090219"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"German\u00e0, E., Pepe, L., Pizzimenti, C., Ballato, M., Pierconti, F., Tuccari, G., Ieni, A., Giuffr\u00e8, G., Fadda, G., and Fiorentino, V. (2024). Programmed Cell Death Ligand 1 (PD-L1) Immunohistochemical Expression in Advanced Urothelial Bladder Carcinoma: An Updated Review with Clinical and Pathological Implications. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25126750"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.cell.2018.03.017","article-title":"Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer","volume":"173","author":"Lee","year":"2018","journal-title":"Cell"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e2414558","DOI":"10.1002\/advs.202414558","article-title":"Patient-Derived Bladder Cancer Organoids as a Valuable Tool for Understanding Tumor Biology and Developing Personalized Treatment","volume":"12","author":"Zhao","year":"2025","journal-title":"Adv. Sci."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/13\/5101\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T11:18:53Z","timestamp":1782818333000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/13\/5101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":55,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["jcm15135101"],"URL":"https:\/\/doi.org\/10.3390\/jcm15135101","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,30]]}}}